Apriligen are developing a one-time gene-modified cell therapy for Diamond-Blackfan Anaemia, a rare bone marrow disease that presents in infancy. Because the therapy uses the patient’s own stem cells, it aims to end lifelong transfusion dependence without the risks of a donor transplant.